PMID- 32863070
OWN - NLM
STAT- MEDLINE
DCOM- 20200928
LR  - 20201218
IS  - 1873-2518 (Electronic)
IS  - 0264-410X (Print)
IS  - 0264-410X (Linking)
VI  - 38
IP  - 41
DP  - 2020 Sep 22
TI  - BCG vaccine may generate cross-reactive T cells against SARS-CoV-2: In silico 
      analyses and a hypothesis.
PG  - 6352-6356
LID - S0264-410X(20)31086-0 [pii]
LID - 10.1016/j.vaccine.2020.08.045 [doi]
AB  - The world is facing the rising emergency of SARS-CoV-2. The outbreak of COVID-19 
      has caused a global public health and economic crisis.Recent epidemiological 
      studies have shown that a possible association of BCG vaccination program with 
      decreased COVID-19-related risks, suggesting that BCG may provide protection 
      against COVID-19. Non-specific protection against viral infections is considered 
      as a main mechanism of BCG and clinical trials to determine whether BCG vaccine 
      can protect healthcare workers from the COVID-19 are currently underway. We 
      hypothesized that BCG may carry similar T cell epitopes with SARS-CoV-2 and 
      evaluated the hypothesis by utilizing publicly available database and computer 
      algorithms predicting human leukocyte antigen (HLA) class I-binding peptides. We 
      foundthatBCG contains similar 9-amino acid sequences with SARS-CoV-2. These 
      closely-related peptides had moderate to high binding affinity for multiple 
      common HLA class I molecules, suggesting that cross-reactive T cells against 
      SARS-CoV-2 could be generated by BCG vaccination.
CI  - Copyright (c) 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Tomita, Yusuke
AU  - Tomita Y
AD  - Department of Respiratory Medicine, Graduate School of Medical Sciences, Kumamoto 
      University, Japan. Electronic address: y-tomita@kumadai.jp.
FAU - Sato, Ryo
AU  - Sato R
AD  - Laboratory of Stem Cell and Neuro-Vascular Biology, Genetics and Developmental 
      Biology Center, National Heart, Lung, and Blood Institute, National Institutes of 
      Health, United States.
FAU - Ikeda, Tokunori
AU  - Ikeda T
AD  - Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Pharmaceutical 
      Sciences, Sojo University, Japan; Department of Medical Information Sciences and 
      Administration Planning, Kumamoto University Hospital, Japan.
FAU - Sakagami, Takuro
AU  - Sakagami T
AD  - Department of Respiratory Medicine, Graduate School of Medical Sciences, Kumamoto 
      University, Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200820
PL  - Netherlands
TA  - Vaccine
JT  - Vaccine
JID - 8406899
RN  - 0 (BCG Vaccine)
RN  - 0 (Epitopes, T-Lymphocyte)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Viral Vaccines)
SB  - IM
MH  - Amino Acid Sequence/genetics
MH  - BCG Vaccine/*immunology
MH  - Betacoronavirus/genetics/*immunology
MH  - CD8-Positive T-Lymphocytes/*immunology
MH  - COVID-19
MH  - Coronavirus Infections/*prevention & control
MH  - Cross Reactions/immunology
MH  - Epitopes, T-Lymphocyte/genetics/*immunology
MH  - Histocompatibility Antigens Class I/immunology
MH  - Humans
MH  - Mycobacterium bovis/genetics/immunology
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/*prevention & control
MH  - SARS-CoV-2
MH  - Viral Vaccines/immunology
PMC - PMC7440160
OTO - NOTNLM
OT  - Bacillus Calmette-Guerin (BCG)
OT  - COVID-19
OT  - Human leukocyte antigen (HLA)
OT  - Pandemic
OT  - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2020/08/31 06:00
MHDA- 2020/09/29 06:00
PMCR- 2020/08/20
CRDT- 2020/09/01 06:00
PHST- 2020/06/04 00:00 [received]
PHST- 2020/07/13 00:00 [revised]
PHST- 2020/08/18 00:00 [accepted]
PHST- 2020/08/31 06:00 [pubmed]
PHST- 2020/09/29 06:00 [medline]
PHST- 2020/09/01 06:00 [entrez]
PHST- 2020/08/20 00:00 [pmc-release]
AID - S0264-410X(20)31086-0 [pii]
AID - 10.1016/j.vaccine.2020.08.045 [doi]
PST - ppublish
SO  - Vaccine. 2020 Sep 22;38(41):6352-6356. doi: 10.1016/j.vaccine.2020.08.045. Epub 
      2020 Aug 20.